文献速递心外重症与机械循环支持

重新审视全球心脏分配系统中IABP患者的优先地位?

Time to rethink the prioritization of IABP patients in heart allocation systems worldwide?
PubMed 文献 · J Heart Lung Transplant · 2025-06-06

本文综述了主动脉内球囊反搏(IABP)的生理效应、在休克与低心排综合征中的应用,以及其在全球心脏移植分配政策中的角色。鉴于IABP-SHOCK II、CRISP MI及ALTSHOCK2等试验未能证实其生存获益,作者呼吁基于强临床证据重新评估IABP在临床实践与移植分配中的地位。

要点

  • IABP-SHOCK II与CRISP MI未显示急性心梗相关心源性休克患者的生存获益。
  • ALTSHOCK2未能证明IABP在心力衰竭相关心源性休克中的临床优势。
  • 在优先考虑IABP支持患者的国家,IABP作为移植桥接使用尤为常见。

核心结论

  • 现有证据不支持IABP在急性心梗相关心源性休克中带来生存获益,ALTSHOCK2也未显示心衰相关心源性休克的临床优势。
  • 作者呼吁依据强临床证据重新评估IABP在临床实践及移植分配政策中的作用。

研究设计与样本

  • 本文为综述,检索并汇总IABP生理效应、休克与低心排应用及全球移植分配政策的相关证据。

主要发现

  • IABP-SHOCK II与CRISP MI等大型随机对照试验未证实急性心梗相关心源性休克的生存获益。
  • ALTSHOCK2研究未能显示IABP治疗在心力衰竭相关心源性休克患者中的临床优势。
  • IABP作为移植桥接在优先考虑IABP支持患者的国家分配系统中尤为常见。

临床怎么用

  • 临床应基于现有随机对照试验证据审慎评估IABP在休克状态及低心排综合征中的应用。
  • 移植分配政策制定者需重新审视将IABP支持作为优先条件的合理性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The intra-aortic balloon pump (IABP) remains widely used in clinical practice despite increasing evidence questioning its efficacy and safety. Designed as a simple temporary mechanical circulatory support device, IABP might offer benefits such as afterload reduction, cardiac output enhancement, and coronary perfusion improvement. However, large randomized controlled trials such as IABP-SHOCK II and CRISP MI have failed to demonstrate a survival benefit in acute myocardial infarction related cardiogenic shock. The ALTSHOCK2 study recently failed to show a clinical advantage of IABP-therapy in patients with heart failure-related cardiogenic shock. The use of IABP as a bridge to transplantation is particularly common in countries where national allocation systems prioritize patients on IABP support. The results of the recent ALTSHOCK2-trial question the justification for its continued inclusion in prioritization models. Hence, we examine the physiological effects of IABP, its application in shock states and low cardiac-output syndrome, and its role in transplantation allocation policies worldwide. In line with the present data, we call for a reevaluation of its role in clinical practice and transplant allocation to align with strong clinical evidence.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Delmas C, Vandenbriele C, Baudry G, et al. Time to rethink the prioritization of IABP patients in heart allocation systems worldwide? J Heart Lung Transplant. 2025. PMID: 40484293. doi:10.1016/j.healun.2025.06.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。